Fig 1: YWHAH positively regulates the mRNA and protein expression of Fra-1. (A) In SGC7901 GC cells, the effect of overexpression of YWHAH on the expression of Fra-1 mRNA was detected using qRT-PCR. (B) In SGC7901 GC cells, the effect of overexpression/interference of YWHAH on the level of the Fra-1 protein was detected using western blotting. (C) In SGC7901 GC cells, the mRNA level of Fra-1 after interference with YWHAH was detected using qRT-PCR. (D) In AGS GC cells, the effect of overexpression of YWHAH on the expression of Fra-1 mRNA was detected using qRT-PCR. (E) Western blotting was used to detect the effect of overexpression/interference of YWHAH on the level of the Fra-1 protein in AGS GC cells. (F) In AGS GC cells, the mRNA level of Fra-1 after interference with YWHAH was detected using qRT-PCR. GAPDH was the internal control, NS: not significant, **p < 0.01, ***p < 0.001. Three independent experiments were conducted.
Fig 2: YWHAH regulates the activity of the HMGA1/PI3K/AKT/mTOR signaling pathway through Fra-1. (A and C) The mRNA levels of HMGA1/PI3K/AKT/mTOR signal pathway-related molecules were detected by qRT-PCR. (B and D) Western blotting detection of the protein level of HMGA1/PI3K/AKT/mTOR signaling pathway-related molecules. NS means: meaningless, *p < 0.05, **p < 0.01, ***p < 0.001, *** p < 0.0001. Internal reference: GAPDH, three independent repeated experiments.
Fig 3: circEHD2-ASO inhibits the growth of RCC in vivo. A, Schematic illustration of tumor inoculation and circEHD2-ASO treatment in subcutaneous xenograft model and orthotopic xenograft model. B–E, Representative images of xenograft tumors (B), dissected tumors (C), the volume of tumors (D), and tumor weights (E) in subcutaneous xenograft model treated with ASO-control (n = 6/group) and circEHD2-ASO (n = 6/group), respectively. F-H, Representative images of in vivo bioluminescence imaging (F), the mean photon counts (G), and gross appearance of orthotopic tumor (H) in orthotopic xenograft model treated with ASO-control (n = 4/group) and circEHD2-ASO (n = 4/group), respectively. I, A schematic model showing the mechanism of EVs-circEHD2 mediated the progression of RCC. FUS mediated the biogenesis of circEHD2, then circEHD2 enhanced the growth of RCC through the circEHD2/YWHAH/YAP/SOX9 pathway. While hnRNPA2B1 mediated the packaging of circEHD2 into EVs, and EVs-circEHD2 promote metastasis of RCC by converting fibroblasts to CAFs. *, P < 0.05; **, P < 0.01; ***, P < 0.001
Fig 4: Schematic diagram of the effect of YWHAH interacting with Fra-1 on the proliferation of gastric cancer cells.
Fig 5: YWHAH affects the proliferation of GC cells by positively regulating Fra-1. (A) YWHAH+siNC, NC+siNC, and YWHAH+siFra-1 plasmids were transfected into SGC7901 GC cells, separately. Cell proliferation was detected using an EdU-647 cell proliferation assay combined with flow cytometry. (B) siYWHAH+ NC, siNC + NC, and siYWHAH+Fra-1 plasmids were transfected into SGC7901 GC cells, separately. Cell proliferation was detected using an EdU-647 cell proliferation assay combined with flow cytometry. (C) YWHAH+siNC, NC+siNC, and YWHAH+siFra-1 plasmids were transfected into AGS GC cells, separately. Cell proliferation was detected using an EdU-647 cell proliferation assay combined with flow cytometry. (D) siYWHAH+ NC, siNC + NC, and siYWHAH+Fra-1 plasmids were transfected into AGS GC cells, separately. Cell proliferation was detected using an EdU-647 cell proliferation assay combined with flow cytometry. ***p < 0.001. Three independent experiments were conducted.
Supplier Page from Abcam for Anti-14-3-3 eta/YWHAH antibody [EPR16750]